Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 06, 2026
DataAggregated Company Financials
Companies7
  • 7D-3.7%
  • 3M1.0%
  • 1Y-11.3%
  • YTD-3.9%

Over the last 7 days, the Life Sciences industry has dropped 3.7%, driven by Lonza Group declining 3.0%. However, the industry is down 11% over the past year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 07 Jun 2026CHF 46.9bCHF 10.1bCHF 1.1b35.9x43x4.6x
Tue, 05 May 2026CHF 46.5bCHF 10.1bCHF 1.1b36.8x40.7x4.6x
Thu, 02 Apr 2026CHF 48.3bCHF 10.1bCHF 1.1b33.6x42.2x4.8x
Sat, 28 Feb 2026CHF 49.7bCHF 10.1bCHF 1.3b30.3x38.6x4.9x
Mon, 26 Jan 2026CHF 52.3bCHF 10.6bCHF 1.1b33.5x47.6x4.9x
Wed, 24 Dec 2025CHF 48.9bCHF 10.6bCHF 1.1b29.7x44.5x4.6x
Fri, 21 Nov 2025CHF 47.6bCHF 10.6bCHF 1.1b27.2x43.3x4.5x
Sun, 19 Oct 2025CHF 50.4bCHF 10.6bCHF 1.1b30x45.8x4.7x
Tue, 16 Sep 2025CHF 51.1bCHF 10.6bCHF 1.1b33.3x46.4x4.8x
Thu, 14 Aug 2025CHF 52.6bCHF 10.7bCHF 1.1b36.2x46.5x4.9x
Sat, 12 Jul 2025CHF 53.1bCHF 10.1bCHF 1.0b33.8x51.1x5.3x
Mon, 09 Jun 2025CHF 53.4bCHF 10.1bCHF 1.0b32.2x51.4x5.3x
Wed, 07 May 2025CHF 54.2bCHF 10.1bCHF 1.0b30.3x52.2x5.4x
Fri, 04 Apr 2025CHF 50.5bCHF 10.1bCHF 1.0b29.9x49.2x5x
Sun, 02 Mar 2025CHF 54.5bCHF 10.1bCHF 1.0b31.2x52.2x5.4x
Tue, 28 Jan 2025CHF 57.2bCHF 10.2bCHF 943.2m36.4x60.6x5.6x
Thu, 26 Dec 2024CHF 52.4bCHF 10.2bCHF 943.5m35.4x55.5x5.1x
Sat, 23 Nov 2024CHF 52.9bCHF 10.2bCHF 943.7m40.8x56.1x5.2x
Mon, 21 Oct 2024CHF 56.1bCHF 10.2bCHF 943.4m42.3x59.5x5.5x
Wed, 18 Sep 2024CHF 56.2bCHF 10.2bCHF 937.0m44.1x60x5.5x
Fri, 16 Aug 2024CHF 56.8bCHF 10.2bCHF 914.5m45.4x62.1x5.6x
Sun, 14 Jul 2024CHF 55.4bCHF 10.3bCHF 1.0b47.5x55.3x5.4x
Tue, 11 Jun 2024CHF 53.1bCHF 10.3bCHF 1.0b43.6x53x5.2x
Thu, 09 May 2024CHF 55.0bCHF 10.3bCHF 1.0b43.6x54.9x5.4x
Sat, 06 Apr 2024CHF 57.1bCHF 10.3bCHF 1.0b45.4x56.9x5.6x
Mon, 04 Mar 2024CHF 50.7bCHF 10.2bCHF 982.2m47x51.7x5x
Wed, 31 Jan 2024CHF 47.0bCHF 10.2bCHF 1.0b41.6x46.1x4.6x
Fri, 29 Dec 2023CHF 41.8bCHF 9.8bCHF 1.5b32.4x28x4.3x
Sun, 26 Nov 2023CHF 41.4bCHF 9.8bCHF 1.5b29.9x27.7x4.2x
Tue, 24 Oct 2023CHF 37.8bCHF 9.8bCHF 1.5b26.5x25.3x3.9x
Thu, 21 Sep 2023CHF 48.2bCHF 9.8bCHF 1.5b33.4x32.3x4.9x
Sat, 19 Aug 2023CHF 51.5bCHF 9.7bCHF 1.5b40.3x33.6x5.3x
Mon, 17 Jul 2023CHF 56.4bCHF 9.7bCHF 1.6b36.1x34.5x5.8x
Wed, 14 Jun 2023CHF 59.0bCHF 9.7bCHF 1.6b37.5x36.1x6.1x
Price to Earnings Ratio

36.1x


Total Market Cap: CHF 59.0bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.0x which is lower than its 3-year average PE of 46.3x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-1.19%
Healthcare-0.74%
Life Sciences-3.73%
Clinical Research and Equipment-3.73%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SKAN SKAN GroupCHF 50.802.4%
+CHF 27.0m		-32.4%PE70.2x
TECN Tecan GroupCHF 156.500.7%
+CHF 13.8m		-4.5%PS2.2x

Latest News

BANB
CHF 68.55
Bachem Holding
7D
-10.8%
1Y
27.1%
Narrative Update • Jun 05

BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework

Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
SKAN
CHF 50.80
SKAN Group
7D
2.4%
1Y
-32.4%
Narrative Update • Jun 03

SKAN: Order Backlog And Dividend Payouts Will Support Future Returns

Analysts have reaffirmed their CHF 62.50 price target for SKAN Group, citing only very small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions rather than any major change in the outlook. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio.
LONN
CHF 485.60
Lonza Group
7D
-3.0%
1Y
-15.3%
SFZN
CHF 78.35
Siegfried Holding
7D
-4.2%
1Y
-19.3%
Narrative Update • Jun 01

SFZN: Steady 2026 Guidance And Refined Views Will Support Future Upside

Analysts have modestly raised their average price target on Siegfried Holding by CHF 4 to reflect updated views on valuation, with one firm lifting its target by CHF 4 while another recently adjusted its target down to CHF 96, keeping expectations broadly in line with prior assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the share price, reflected in the CHF 4 upward adjustment.
TECN
CHF 156.50
Tecan Group
7D
0.7%
1Y
-4.5%
Narrative Update • May 31

TECN: Reduced P/E Expectations Will Limit Perceived Upside Potential

Analysts have trimmed their price targets on Tecan Group by CHF 1 to CHF 10 in recent updates. This reflects revised assumptions around discount rates, profit margins and future P/E expectations.
PPGN
CHF 36.40
PolyPeptide Group
7D
-4.0%
1Y
70.1%